February 11, 2011 – The U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) has launched the Medical Device Innovation Initiative. The initiative proposes actions the CDRH could take to help accelerate and reduce the cost of development and regulatory evaluation of innovative medical devices safely and based on sound science.

February 11, 2011 – A technology integration strategy will provide clinicians with a host of new noninvasive, continuous measurements and patient-monitoring capabilities. The joint strategy, between Welch Allyn and Masimo, will make the Masimo rainbow SET Pulse CO-Oximetry platform a fundamental offering in Welch Allyn’s product line-up.

February 11, 2011 – A power-injectable, extended-dwell catheter has gotten the CE Mark. The Powerwand, from Access Scientific, is placed using the Accelerated Seldinger Technique, and promises to improve the inpatient experience while increasing worker safety.

February 11, 2011 — Exam-Pad Model 10 is the first turnkey picture archiving and commuication systems (PACS) tablet that combines instant, virtual, worldwide wireless access to medical images in a Windows 7 Professional environment.

February 10, 2011 – A study at Millard Fillmore Circle Gates Hospital in Buffalo, N.Y., found that Toshiba imaging equipment presented significant benefits, both for the patients and hospital.

February 10, 2011 – A new bill introduced to the U.S. Senate aims to promote sustainable, domestic production of the medical isotope molybdenum-99 (Mo-99). The bill, also known as the American Medical Isotopes Production Act of 2011, was introduced by Sen. Jeff Bingaman (D-N.M.) and Sen. Lisa Murkowski (R-Ark.).

Bingaman is chair of the Senate Committee on Energy and Natural Resources.

February 10, 2011 – Only about two out of every 100 babies (1.8 percent) are screened at birth for congenital heart defects (CHDs) because the hospital or birthing center does not routinely screen all newborns. CHDs are the No. 1 birth defect and leading killer of infants and newborns.

February 10, 2011 – Never before has a therapy proven more beneficial for women than men in preventing heart disease – until now.

February 10, 2011 – A Phase 2 clinical trial has been initiated to test the safety and efficacy of drug to reverse heparin in patients undergoing percutaneous coronary intervention (PCI). The trial will assess PolyMedix’s heptagonist, PMX-60056, a synthetic small-molecule designed to reverse the anticoagulation activity of heparin and low molecular weight heparins (LMWH).

February 9, 2011 – The first patients have been enrolled in a trial investigating the safety and efficacy of a system that removes clot from acute ischemic stroke patients. The Trevo 2 study will look at the Trevo Retriever device, from Concentric Medical.

It is the first device to use Stentriever technology for retrieving clots from the neurovasculature.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now